| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Retinoid receptors (e.g., RAR or RXR) are the primary targets for Tazarotene and other retinoids. As a Tazarotene derivative, WYC-210 likely interacts with these nuclear receptors, although its specific binding affinity and selectivity have not been fully characterized. Its reported lower anticancer activity compared to Tazarotene suggests a potentially different or reduced interaction with these targets.
|
|---|---|
| ln Vitro |
B16-F1 TRC cell proliferation is inhibited by WYC-210 (10 μM; 5 days) with an inhibition rate of 18.1%[1].
WYC-210 has been evaluated in vitro for its effects on cell growth. At a concentration of 10 μM over 5 days, it inhibited the growth of B16-F1 TRC cells, with an inhibition rate of 18.1%. This low level of activity is consistent with its description as a compound with lower anticancer properties. Its primary in vitro utility is as a chemical probe or a building block for more complex molecules via click chemistry. |
| ln Vivo |
In vivo data for WYC-210 are not available in the public domain. As a research compound with lower biological activity, it is likely used primarily as a negative control or for chemical biology applications rather than for therapeutic efficacy studies in animal models.
|
| Enzyme Assay |
Non-cell-based assays for WYC-210 are not typically performed to assess biological activity, as it is not a primary drug candidate. Its characterization involves standard analytical chemistry methods to confirm its structure and purity. This includes High-Performance Liquid Chromatography (HPLC), Nuclear Magnetic Resonance (NMR) spectroscopy, and Mass Spectrometry (MS). Its utility as a click chemistry reagent is verified by demonstrating its ability to undergo CuAAc reactions.
|
| Cell Assay |
Cell-based assays for WYC-210 have been conducted to assess its anticancer activity. In one study, B16-F1 TRC cells were treated with WYC-210 at a concentration of 10 μM for 5 days, and cell growth inhibition was measured, yielding an inhibition rate of 18.1%. This assay is typically performed to compare its activity against more potent retinoids like Tazarotene.
|
| Animal Protocol |
In vivo animal studies for WYC-210 are not documented in the available literature. Its classification as a compound with lower anticancer activity and primary use as a chemical reagent suggests that it is not intended for efficacy studies in animal models of cancer.
|
| ADME/Pharmacokinetics |
WYC-210 has a molecular weight of 340.40 g/mol and the formula C₁₈H₁₆N₂O₃S. It is soluble in DMSO. Its CAS number is 2131803-93-3. As a click chemistry reagent, it contains an alkyne group for CuAAc reactions. The compound should be stored as a powder at -20°C, where it is stable for up to 3 years.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for WYC-210 are not available. As a research chemical with low biological activity, it is presumed to have a manageable safety profile for laboratory use. However, standard precautions for handling chemical reagents should be observed, including the use of personal protective equipment.
|
| References |
[1]. Cao, Xin, et al. Preparation of the retinoid compound and their application as anticancer agents. WO2017152725A1.
|
| Additional Infomation |
WYC-210 is a research compound, a Tazarotene derivative that is a retinoid with low anticancer activity. Its primary value lies in its role as a click chemistry reagent, containing an alkyne group for copper-catalyzed azide-alkyne cycloaddition (CuAAc). It is not intended for therapeutic use and is used as a tool in chemical biology and drug discovery.
|
| Molecular Formula |
C18H16N2O3S
|
|---|---|
| Molecular Weight |
340.396243095398
|
| Exact Mass |
340.088
|
| CAS # |
2131803-93-3
|
| Related CAS # |
WYC-209;2131803-90-0
|
| PubChem CID |
130417724
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
584
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1(CCS(=O)C2=C1C=C(C=C2)C#CC3=NC=C(C=N3)C(=O)O)C
|
| InChi Key |
NENFGFHRYIOMTM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16N2O3S/c1-18(2)7-8-24(23)15-5-3-12(9-14(15)18)4-6-16-19-10-13(11-20-16)17(21)22/h3,5,9-11H,7-8H2,1-2H3,(H,21,22)
|
| Chemical Name |
2-[2-(4,4-dimethyl-1-oxo-2,3-dihydrothiochromen-6-yl)ethynyl]pyrimidine-5-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (146.89 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9377 mL | 14.6886 mL | 29.3772 mL | |
| 5 mM | 0.5875 mL | 2.9377 mL | 5.8754 mL | |
| 10 mM | 0.2938 mL | 1.4689 mL | 2.9377 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
